CEDAR KNOLLS, N.J., Nov. 24, 2008 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (NasdaqCM:EMIS - News) announced today the results of a study by Novartis Pharma AG which demonstrates the achievement of a suitable PK profile of a new oral formulation of Parathyroid Hormone (``PTH’’) using Emisphere’s Eligen(r) Technology. This initial study of 20 healthy postmenopausal female patients aged 40 to 70 years resulted in peak concentrations (CMAX) in the range of those obtained with the commercially available subcutaneous formulation Forteo (teriparatide). The plan is to continue the development program.
